Clinical outcomes with the use of aspirin vs. clopidogrel as a combination therapy with direct oral anticoagulant after coronary stent implantation in patients with atrial fibrillation
Main finding · MACE (composite of cardiovascular death, myocardial infarction, ischaemic stroke, or systemic thromboembolism)Result — go to the resultHazard ratio 0.91 95% CI 0.81–1.02Authors' conclusion
In patients with AF receiving double antithrombotic therapy after PCI, aspirin and clopidogrel showed similar efficacy and safety when used in combination with DOAC.
Study context
- Population
- Patients with atrial fibrillation (AF) who received double antithrombotic therapy consisting of an antiplatelet agent and a direct oral anticoagulants (DOAC) after percutaneous coronary intervention (PCI), Korea National Health Insurance Service, 2013 to 2020patients included before propensity score (PS) matching, 2882 per group after matching
- Participants
- 9,157 patients
- Comparison
- Aspirin vs. clopidogrel as a combination therapy with DOAC
- Clopidogrel groupn = 2,882
- Aspirin groupn = 2,882reference
- Outcome
- Major adverse cardiovascular event (MACE):
- Cardiovascular death
- Myocardial infarction
- Ischaemic stroke
- Systemic thromboembolism
- Follow-up
- Median 20.1 months
Methodological details1:1 propensity score (PS) matching
- 1:1 propensity score (PS) matching
Main finding
As reported in the abstract
Hazard ratio
0.91
95% CI 0.81–1.02
Clopidogrel groupvs aspirin group
HR 0.91 (95% CI 0.81–1.02)
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Net adverse clinical eventsSignificant difference not observed | 0.93 (0.84–1.03) | |
| 0.512Hazard ratio (log scale) |
Ischaemic endpoints
- Did not significantly differ between the two groups
Safety
| Outcome | HR (95% CI) | |
|---|---|---|
| Major bleeding eventsSignificant difference not observed | 0.94 (0.78–1.12) | |
| 0.512Hazard ratio (log scale) |
Original publication
Clinical outcomes with the use of aspirin vs. clopidogrel as a combination therapy with direct oral anticoagulant after coronary stent implantation in patients with atrial fibrillation. Eur Heart J Cardiovasc Pharmacother. Published 29 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →